Verastem Company Profile (NASDAQ:VSTM)

About Verastem (NASDAQ:VSTM)

Verastem logoVerastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:VSTM
  • CUSIP: 92337C10
  • Web: N/A
  • Market Cap: $88.78 million
  • Outstanding Shares: 36,992,000
Average Prices:
  • 50 Day Moving Avg: $2.06
  • 200 Day Moving Avg: $1.48
  • 52 Week Range: $1.05 - $2.54
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.67
  • P/E Growth: -1.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.63 per share
  • Price / Book: 1.47
  • EBIDTA: ($41,080,000.00)
  • Average Volume: 513,265 shs.
  • Short Ratio: 0.45

Frequently Asked Questions for Verastem (NASDAQ:VSTM)

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) posted its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.35) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.35) by $0.00. View Verastem's Earnings History.

Where is Verastem's stock going? Where will Verastem's stock price be in 2017?

6 analysts have issued 12-month price objectives for Verastem's shares. Their forecasts range from $1.50 to $6.50. On average, they anticipate Verastem's share price to reach $4.00 in the next year. View Analyst Ratings for Verastem.

What are analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:

  • 1. According to Zacks Investment Research, "Verastem, Inc. is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. The company discovers, researches, and develops new medicines for the treatment of major cancers such as breast cancer. Verastem, Inc. is based in Cambridge, Massachusetts. " (5/16/2017)
  • 2. Cann analysts commented, "Verastem’s loss per share of $0.35 was less than our estimated $0.37. This was the result of slightly lower than estimated operating expenses, which were $13.1 million compared to our estimated $13.8 million. Our outlook for 2017-2021 remains basically unchanged other than minor adjustments to interest income and SG&A, which only impact EPS in 2020." (5/11/2017)
  • 3. Cantor Fitzgerald analysts commented, "DYNAMO Follow-Up Data Coming Soon. VSTM will present follow-up data with duvelisib in double-refractory indolent non-Hodgkin lymphoma (iNHL) at the International Conference on Malignant Melanoma (ICML), commonly referred to as the Lugano Meeting" on June 15th. We think these data could provide support for duvelisib, should the long-term data prove to be durable. Rethinking Duvelisib. Duvelisib’s past history as a development candidate is potentially masking its true market opportunity, as the drug could be used in Imbruvica failures. We don’t view the outcome of the DUO trial as slam dunk", but we do think that the drug’s potential has been overshadowed by its previous history. The drug is being compared to Novartis’ (Not Covered) Arzerra (ofatumumab), and tested in a setting of relapsed/refractory CLL. Optionality with Defactinib. While duvelisib will be the key driver for the value expansion near term, in our view, VSTM is also continuing development of defactinib. Given the prior history of defactinib (COMMAND) it also appears to us that the clinical profile may not be recognized until additional data are in hand, particularly as some of the work is being conducted via investigator- sponsored trials (ISTs)." (5/11/2017)
  • 4. HC Wainwright analysts commented, "According to management, the topline results from the Phase 3 DUO study of duvelisib (a PI3K-??/PI3K-?? inhibitor) for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) are expected around mid-year 2017. Recall, DUO is a 300-patient, randomized, controlled study comparing the use of duvelisib monotherapy to ofatumumab, an anti-CD20 antibody marketed as Arzerra by Novartis (NVS; not rated), for the treatment of CLL, with the primary endpoint of progression-free survival (PFS) and secondary endpoints that include overall response rate (ORR) and overall survival (OS). Based on results from earlier stage studies in CLL as well as the previously completed DYNAMO study in indolent non-Hodgkin's lymphoma (iNHL), we believe that DUO is highly likely to meet its primary PFS endpoint. Furthermore, while many investors have doubts regarding duvelisib's commercial outlook in the competitive CLL indication, we believe that, even with less-than-stellar results from DUO, the drug has the potential to capture a material portion of the highly lucrative market for 2nd/3rd-line CLL treatments. Therefore, we expect positive results from the DUO study to be a significant catalyst for the company. Based on our analysis of duvelisib's commercial potential, we are increasing our price target to $6.50 per diluted share, up from $5.00." (3/24/2017)

Who are some of Verastem's key competitors?

Who owns Verastem stock?

Verastem's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.32%), Deer VII & Co. Ltd. (3.22%), Vanguard Group Inc. (2.80%), FMR LLC (1.89%), Stifel Financial Corp (1.01%) and Nexthera Capital LP (0.91%). Company insiders that own Verastem stock include Dan Paterson, Michael Kauffman, Monica Singh, Robert Forrester and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Who sold Verastem stock? Who is selling Verastem stock?

Verastem's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, AWM Investment Company Inc., Stoneridge Investment Partners LLC, UBS Group AG, Howland Capital Management LLC and Stifel Financial Corp. View Insider Buying and Selling for Verastem.

Who bought Verastem stock? Who is buying Verastem stock?

Verastem's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, TFS Capital LLC, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought Verastem stock in the last two years include Dan Paterson, Monica Singh, Robert Forrester and Timothy J Barberich. View Insider Buying and Selling for Verastem.

How do I buy Verastem stock?

Shares of Verastem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Verastem stock cost?

One share of Verastem stock can currently be purchased for approximately $2.40.

Analyst Ratings

Consensus Ratings for Verastem (NASDAQ:VSTM) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $4.00 (66.67% upside)

Analysts' Ratings History for Verastem (NASDAQ:VSTM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017Oppenheimer Holdings Inc.Set Price TargetBuy$6.00MediumView Rating Details
5/11/2017CannReiterated RatingBuy$2.00LowView Rating Details
5/11/2017Cantor FitzgeraldReiterated RatingHold$2.00HighView Rating Details
4/13/2017CIBCReiterated RatingOutperform -> Outperform$6.00HighView Rating Details
3/24/2017HC WainwrightBoost Price TargetBuy -> Buy$5.00 -> $6.50HighView Rating Details
8/5/2016Jefferies Group LLCReiterated RatingHold$1.50N/AView Rating Details
9/29/2015JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
9/29/2015Raymond James Financial, Inc.DowngradeStrong-Buy -> Outperform$12.00 -> $3.00N/AView Rating Details
9/28/2015MizuhoDowngradeBuy -> Neutral$21.00 -> $2.00N/AView Rating Details
9/28/2015Roth CapitalDowngradeBuy -> Neutral$23.00 -> $2.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Verastem (NASDAQ:VSTM)
Earnings by Quarter for Verastem (NASDAQ:VSTM)
Earnings History by Quarter for Verastem (NASDAQ:VSTM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.35)($0.35)ViewN/AView Earnings Details
11/7/2016Q3($0.24)($0.21)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.23)ViewN/AView Earnings Details
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details
11/12/2013Q3($0.44)($0.47)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Verastem (NASDAQ:VSTM)
2017 EPS Consensus Estimate: ($1.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.37)($0.37)($0.37)
Q2 20171($0.36)($0.36)($0.36)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)


Dividend History for Verastem (NASDAQ:VSTM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Verastem (NASDAQ:VSTM)
Insider Trades by Quarter for Verastem (NASDAQ:VSTM)
Institutional Ownership by Quarter for Verastem (NASDAQ:VSTM)
Insider Trades by Quarter for Verastem (NASDAQ:VSTM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Timothy J BarberichDirectorBuy30,000$2.45$73,500.00View SEC Filing  
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00View SEC Filing  
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.00View SEC Filing  
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00View SEC Filing  
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00View SEC Filing  
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00View SEC Filing  
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00View SEC Filing  
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00View SEC Filing  
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00View SEC Filing  
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00View SEC Filing  
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00View SEC Filing  
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00View SEC Filing  
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00View SEC Filing  
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00View SEC Filing  
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00View SEC Filing  
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00View SEC Filing  
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00View SEC Filing  
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Verastem (NASDAQ:VSTM)
Latest Headlines for Verastem (NASDAQ:VSTM)
DateHeadline logoVerastem (VSTM) Announces Duvelisib Data Presentations at EHA - - May 19 at 1:39 PM logoVerastem (VSTM) Announces Duvelisib Data Presentations at EHA - May 18 at 10:07 AM logoVerastem Inc (VSTM) Director Acquires $73,500.00 in Stock - May 17 at 10:22 AM logoVerastem Inc (VSTM) Cut to "Sell" at Zacks Investment Research - May 16 at 2:08 PM logoQ2 2017 Earnings Forecast for Verastem Inc Issued By Oppenheimer Holdings (VSTM) - May 15 at 7:02 AM logoVerastem Inc (VSTM) Releases Earnings Results - May 11 at 4:26 PM logoVerastem Inc (VSTM) Given a $6.00 Price Target by Oppenheimer Holdings Inc. Analysts - May 11 at 2:56 PM logoVerastem Inc (VSTM) Earns Buy Rating from Cann - May 11 at 9:09 AM logoZacks: Brokerages Expect Verastem Inc (VSTM) to Announce -$0.34 Earnings Per Share - May 11 at 9:06 AM logoVerastem's (VSTM) Hold Rating Reaffirmed at Cantor Fitzgerald - May 11 at 8:28 AM logoVerastem reports 1Q loss - May 11 at 3:18 AM logoBioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience - May 10 at 9:55 AM logoVerastem Inc (VSTM) Given Average Rating of "Buy" by Brokerages - May 8 at 4:36 PM logoVerastem Inc (VSTM) to Release Quarterly Earnings on Monday - May 6 at 7:04 AM logoOppenheimer Holdings Comments on Verastem Inc's Q2 2017 Earnings (VSTM) - May 5 at 7:37 AM logoResearch Analysts Offer Predictions for Verastem Inc's Q1 2017 Earnings (VSTM) - May 4 at 10:46 AM logoVerastem (VSTM) Announces Long Term Follow-up Data from DYNAMO Study to be Presented at ICML - May 3 at 11:55 PM logoVerastem (VSTM) Given Media Sentiment Score of 0.09 - May 3 at 6:08 PM logoVerastem Announces Long Term Follow-up Data from the DYNAMO Study Selected for Oral Presentation at the 14th International Conference on Malignant Lymphoma - May 3 at 9:51 AM logoVerastem Appoints Eric K. Rowinsky to the Board of Directors - May 2 at 8:22 AM logoSomewhat Positive News Coverage Extremely Likely to Affect Verastem (VSTM) Stock Price - April 30 at 8:58 AM logoVerastem (VSTM) Earns Media Impact Score of 0.44 - April 27 at 10:56 AM logoVerastem (VSTM) Getting Somewhat Favorable Media Coverage, Study Finds - April 24 at 10:20 AM logoSomewhat Positive Media Coverage Somewhat Likely to Affect Verastem (VSTM) Stock Price - April 20 at 3:06 PM logo Brokerages Expect Verastem Inc (VSTM) Will Post Earnings of -$0.36 Per Share - April 20 at 1:01 PM logoFavorable News Coverage Somewhat Likely to Impact Verastem (VSTM) Stock Price - April 17 at 8:52 AM logoToday's Research Reports on Biotech Stocks to Watch: Ocera Therapeutics and Verastem - April 17 at 8:13 AM logoVerastem Inc (VSTM) Short Interest Up 71.0% in March - April 15 at 5:56 PM logoVerastem (VSTM) Receiving Somewhat Positive Media Coverage, Report Finds - April 14 at 12:34 PM logoVerastem Inc (VSTM) Receives Average Rating of "Buy" from Analysts - April 13 at 1:08 PM logoVerastem Inc (VSTM) Coverage Initiated by Analysts at Oppenheimer Holdings Inc. - April 13 at 1:00 PM logoVerastem Inc (VSTM) Receives New Coverage from Analysts at CIBC - April 13 at 12:34 PM logoVerastem Inc (VSTM) Coverage Initiated by Analysts at Cann - April 12 at 10:15 PM logo3:34 am Verastem reports Data on Verastem's Focal Adhesion Kinase Inhibitor Defactinib; supports ongoing clinical study evaluating defactinib in combination with pembrolizumab and gemcitabine - April 3 at 8:42 PM logoVerastem to Present at the 16th Annual Needham Healthcare Conference - April 3 at 8:42 PM logoData on Verastem’s Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting - April 3 at 2:09 AM logoVerastem Inc (VSTM) Price Target Raised to $6.50 - March 30 at 9:09 AM logoVERASTEM, INC. Financials - March 30 at 8:17 AM logoEdited Transcript of VSTM earnings conference call or presentation 23-Mar-17 8:30pm GMT - March 24 at 3:33 PM logoVerastem Inc (VSTM) Price Target Raised to $6.50 at HC Wainwright - March 24 at 10:46 AM logoVerastem Reports Year-End 2016 Financial Results - March 23 at 8:54 PM logoVERASTEM, INC. Files SEC form 10-K, Annual Report - March 23 at 8:54 PM logoVerastem Inc Earnings Call scheduled for 4:30 pm ET today - March 23 at 8:54 PM logoVerastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights - March 16 at 3:35 PM logoVerastem to Present at the Oppenheimer 27th Annual Healthcare Conference - March 16 at 6:32 AM logoVerastem to Present at the 29th Annual ROTH Conference - March 7 at 8:21 AM logoVerastem to Present at 19th Annual BIO CEO & Investor Conference - February 7 at 3:38 PM logoVerastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer - January 27 at 6:41 AM logoInfinity Pharma Surges On Latest Cancer Drug Hope - January 25 at 4:25 PM logoVerastem Announces Executive Leadership Appointments and ... - Yahoo Finance - January 20 at 3:35 PM



Verastem (VSTM) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff